{"description":"Only adverse events grade 3 and greater will be collected. Adverse events were obtained through medical chart review and self-reporting by participants.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":32,"description":"On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose. Antibody and cellular response to vaccination will be assessed at 4 weeks and 24 months after the second dose.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":32,"seriousNumAffected":1,"seriousNumAtRisk":32,"title":"Shingrix Vaccine"}],"frequencyThreshold":"0","seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":32,"numEvents":1}],"term":"Atrial fibrillation"}],"timeFrame":"Adverse events were collected from day one to four weeks after the second vaccine administration, up to approximately 3 months."}